Holen Sie sich die Stockscreener-App
0.721
0.55%
-0.004
Schlusskurs vom Vortag:
$0.725
Offen:
$0.75
24-Stunden-Volumen:
110.17K
Relative Volume:
0.28
Marktkapitalisierung:
$23.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.23M
KGV:
-0.559
EPS:
-1.2898
Netto-Cashflow:
$-41.53M
1W Leistung:
-9.82%
1M Leistung:
-23.39%
6M Leistung:
-77.82%
1J Leistung:
-74.70%
1-Tages-Spanne:
$0.7182
$0.7548
1-Wochen-Bereich:
$0.6853
$0.84
52-Wochen-Spanne:
$0.6844
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Firmenname
Skye Bioscience Inc
Sektor
Branche
Telefon
(858) 410-0266
Adresse
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
2.22 | 3.25B | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
8.69 | 536.01M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.32 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
2.8999 | 277.51M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DWLD
Davis Select Worldwide ETF
|
46.01 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-08-15 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-09-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Skye Bioscience, Inc. (SKYE) And Encourages Shareholders to Connect | NDAQ:SKYE | Press Release - Stockhouse
Aug EndMonth: How does IHS Holding Limited compare to its peersJuly 2025 Institutional & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Whats the outlook for Skye Bioscience Incs sectorTrade Analysis Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Retail Trends: Does Skye Bioscience Inc have a competitive edgeJuly 2025 PreEarnings & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Aug Analyst Calls: Will Skye Bioscience Inc benefit from government policy2025 Valuation Update & Precise Trade Entry Recommendations - baoquankhu1.vn
Movement Recap: Can Skye Bioscience Inc weather a recessionMarket Rally & Long-Term Capital Growth Strategies - baoquankhu1.vn
Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely - Sahm
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 - Investing.com Australia
William Blair Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating - 富途牛牛
Skye Bioscience: Nimacimab’s Emerging Clinical Profile and Undervalued Asymmetric Risk/Reward Support Buy Rating - TipRanks
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Benzinga
Skye Bioscience (SKYE) Reports Promising Results from CBeyond Ex - GuruFocus
Skye Bioscience announces 52-week data from Phase 2a CBeyond study of nimacimab - TipRanks
Skye reports positive Cbeyond phase 2a extension interim study results for nimacimab - marketscreener.com
Skye Bioscience Reports Interim Results from Phase 2a Study of Nimacimab - TradingView
Skye, Inc. Announces Interim Results from the Combination Cohort of the Company's Phase 2A Extension Study of Nimacimab - marketscreener.com
Obesity drug combo keeps weight off: Skye study shows 22.3% loss - Stock Titan
Chart Watch: Can Skye Bioscience Inc weather a recessionWeekly Trend Summary & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Skye Reports Positive CBeyond Phase 2a Extension Interim - GlobeNewswire
Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period - MSN
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Stockholders to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
Skye Bioscience reports positive results for obesity drug nimacimab By Investing.com - Investing.com South Africa
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Skye Bioscience reports positive results for obesity drug nimacimab - Investing.com
Skye Bioscience (SKYE) Highlights Promising Obesity Treatment Re - GuruFocus
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference - The Manila Times
Skye Bioscience Highlights Attributes of its - GlobeNewswire
Investment Report: Can Skye Bioscience Inc beat the S P 500Earnings Miss & Safe Capital Growth Stock Tips - baoquankhu1.vn
Portfolio Shifts: Will CREG stock hit new highs in YEARJuly 2025 WrapUp & Smart Money Movement Tracker - baoquankhu1.vn
2026-01-27 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Skye Bioscience, Inc. (SKYE) and Encourages Stockholders to Learn More About the Investigation | NDAQ:SKYE | Press Release - Stockhouse
Revenue Check: Can Skye Bioscience Inc beat the S P 5002025 Volume Leaders & Weekly Top Stock Performers List - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Investors to Inquire about Securities Investigation - accessnewswire.com
2026-01-25 | Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, Inc. (SKYE) Investors to Inquire about Securities Investigation | NDAQ:SKYE | Press Release - Stockhouse
Aug Retail: Can Skye Bioscience Inc weather a recessionEarnings Recap Summary & Detailed Earnings Play Strategies - baoquankhu1.vn
Skye Bioscience to Present Research on Nimacimab at Keystone Conference on Obesity Therapeutics - Quiver Quantitative
Skye Bioscience to Present Poster at Keystone Obesity Conference - The Manila Times
Resistance Check: Will Skye Bioscience Inc outperform the market in YEAR2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Skye Bioscience, Inc. (SKYE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Skye Bioscience Faces Class Action for Securities Fraud, Investors Encouraged to Join - Intellectia AI
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Se - GuruFocus
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
SKYE DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Skye Bioscience, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bios - GuruFocus
Skye Bioscience, Inc. Class Action Reminder: Lead Plaintiff Deadline January 16, 2026 - Intellectia AI
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit - Prime Publishers, Inc.
Skye Bioscience, Inc. (NASDAQ: SKYE) Investor NOTICE: Deadline in Lawsuit on January 16, 2026 - openPR.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - TMX Newsfile
Levi & Korsinsky Announces the Filing of a Securities Class - GlobeNewswire
Finanzdaten der Skye Bioscience Inc-Aktie (SKYE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):